Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Start-ups

AstraZeneca, Scorpion sign transcription factor deal

by Michael McCoy
January 23, 2022 | A version of this story appeared in Volume 100, Issue 3

 

AstraZeneca will pay Scorpion Therapeutics $75 million in a deal to develop small-molecule oncology drugs that target transcription factors, proteins that control gene expression. Transcription factors have long been considered targets for cancer treatments but were considered undruggable using conventional approaches. Scorpion was launched in 2020 by chemist Gary Glick and others. It has raised $270 million in two financing rounds.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.